Bevacizumab Treatment For Type 1 ROP

Key facts

Sponsor

Jaeb Center for Health Research

Principal Investigator

David K Wallace, MD, MPH

Vanderbilt University

Intervention

Bevacizumab(drug)

Enrollment

77 target

Eligibility

All sexes

Timeline

2022 – 2027

Study locations (26)

• Arkansas Childrens Hospital/ University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
• Univ of California, Irvine- Gavin Herbert Eye Institute, Irvine, California, United States
• Jules Stein Eye Institute at the University of California, Los Angeles, Los Angeles, California, United States
• University of California, Davis, Sacramento, California, United States
• University of California San Francisco Department of Ophthalmology, San Francisco, California, United States
• The Emory Eye Center, Atlanta, Georgia, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
• U of Illinois at Chicago Eye and Ear Infirmary, Chicago, Illinois, United States
• University of Chicago, Hyde Park, Illinois, United States
• Indiana University School of Medicine, Indianapolis, Indiana, United States
• Riley Hospital for Children, Indianapolis, Indiana, United States
• UK Ophthalmology and Visual Sciences, The Eye Clinic, Lexington, Kentucky, United States
• Greater Baltimore Medical Center, Baltimore, Maryland, United States
• Boston Children's Hospital, Boston, Massachusetts, United States
• New York Presbyterian David H Koch Center, New York, New York, United States
• +11 more locations on ClinicalTrials.gov

Collaborators

Pediatric Eye Disease Investigator Group · National Eye Institute (NEI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Retinopathy of prematurity

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07093255
  Safety, PK and PD of FLQ-101 in Premature Neonates
  FELIQS INC.
• RECRUITINGNCT06612541
  Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT07334652
  Pain and Comfort in the Examination of Retinopathy of Prematurity
  Ataturk University
• RECRUITINGNANCT06717412
  Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
  Wang Yusheng
• RECRUITINGNCT05558059
  Imaging Retinal Vasculature in Infant Eyes
  Duke University
• ACTIVE NOT RECRUITINGNANCT06109285
  Validation of i-ROP DL to Detect More Than Mild ROP
  Siloam Vision
• RECRUITINGNCT06315556
  An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
  Bayer
• RECRUITINGNANCT06694103
  The Effect of Two Non-Pharmacological Methods on Pain During Retinopathy Examination
  Sinem Basdemir

See all trials for Retinopathy of prematurity →